Vimseltinib is a small molecule commercialized by Deciphera Pharmaceuticals, with a leading Phase III program in Tenosynovial Giant Cell Tumor. According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Vimseltinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Vimseltinib is expected to reach an annual total of $154 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vimseltinib (DCC-3014) is under development for the treatment of advanced malignancies such as solid tumors and tenosynovial giant cell tumor. It is administered orally. The drug candidate acts by targeting the FMS kinase (also known as CSF1R). It is developed based on kinase inhibitor technology. It was also under development for the treatment of glioma, renal cell carcinoma and osteolytic cancer.
It was also under development for the treatment of acute myeloid leukemia (AML), colorectal cancer, bone metastasis, prostate cancer, myelodysplastic syndrome (MDS), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL).
Deciphera Pharmaceuticals Overview
Deciphera Pharmaceuticals is a research and development company that develops, designs and commercializes kinase-inhibiting drugs. The company provides a clinical pipeline of kinase inhibitors such as tumor-targeted therapies and immuno-targeted therapies. It uses proprietary switch control inhibitor platform for discovering and developing kinase inhibitors. Deciphera Pharmaceuticals products are used in the treatment of renal and colon cancers, mastocytosis, gastrointestinal stromal tumors, Crohn’s disease and autoimmune nephritis, solid tumors and rheumatoid arthritis. The company’s products are used in the treatment of immunological diseases and cancers. It markets its products through medical representatives. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts, the US
The company reported revenues of (US Dollars) US$134 million for the fiscal year ended December 2022 (FY2022), an increase of 39.4% over FY2021. The operating loss of the company was US$182.7 million in FY2022, compared to an operating loss of US$300.1 million in FY2021. The net loss of the company was US$178.9 million in FY2022, compared to a net loss of US$300 million in FY2021. The company reported revenues of US$33.5 million for the first quarter ended March 2023, a decrease of 8% over the previous quarter.
For a complete picture of Vimseltinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.